Bioblast Pharma

Hope should not be rare

Robert Friedman

Robert Friedman

Bioblast Pharma Board of Directors Member

Robert Friedman joined the Bioblast Pharma Board of Directors in October 2016. Robert Friedman is a Managing Director in the Navigant Healthcare Life Science practice. Robert co-founded Easton Associates following a nine-year period in management consulting at The Wilkerson Group and IBM Consulting.

During his consulting career, Robert has led and executed hundreds of strategy, market assessment and business development projects covering pharmaceuticals, biotechnology and medical devices. He has performed due diligence assignments on dozens of acquisition and licensing candidates. Robert has taken a particular interest in the flourishing life sciences market in Israel where he has conducted about two dozen discrete assignments. These engagements include diligence work for U.S. companies interested in Israeli technology as well as assessments and entry strategies into the U.S. market.

Prior to his career in management consulting, Robert worked on Wall Street where he was a Senior Equities Analyst in biotechnology, during which time he initiated and maintained coverage of a dozen large- and small-cap biotechnology companies and tracked a universe of approximately 75 companies, primarily in biopharmaceuticals. Robert also spent two years at the venture capital firm, Steinberg & Lyman Healthcare Ventures (now called HealthCare Ventures LLC). He founded and wrote the business plans for several new startups including Genetic Therapy, Inc., which was acquired by Novartis.

Learn about other members of the Board of Directors of Bioblast